Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis

Endocrine Journal

Volumn 55, Issue 1, 2008, Pages 127-134

  Majima, Takafumi ^a,b,c,d   Komatsu, Yasato ^b   Shimatsu, Akira ^a   Satoh, Noriko ^a   Fukao, Atsushi ^c   Ninomiya, Kiyoshi ^c   Matsumura, Tadashi ^c   Nakao, Kazuwa ^b  

^a Center for Endocrine and Metabolic Diseases   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RAKUWAKAI OTOWA HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Alfacalcidol; BMD; Osteoporosis; Raloxifene

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; RALOXIFENE; 1-HYDROXYCHOLECALCIFEROL; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; HYDROXYCOLECALCIFEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; RADIUS; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; BONE REMODELING; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; PATIENT COMPLIANCE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYCHOLECALCIFEROLS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; RALOXIFENE; TREATMENT OUTCOME;

EID: 42049111828     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07E-027     Document Type: Article

References (33)

1. Ettinger B, Black DM, Mitlak BH, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645.
2. Morii H, Ohashi Y, Taketani Y, et al. (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 14: 793-800.
3. Delmas PD, Bjarnason NH, Mitlak BH, et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647.
4. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160: 3444-3450.
5. Uusi-Rasi K, Beck TJ, Semanick LM, et al. (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17: 575-586.
6. Siris ES, Harris ST, Eastell R, Z et al.; Continuing Outcomes Relevant to Evista (CORE) Investigators (2005) Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 20: 1514-1524.
7. Orimo H, Hashimoto T, Sakata K, et al. (2000) Trends in the incidence of hip fracture in Japan, 1987-1997: the third nationwide survey. J Bone Miner Metab 18: 126-131.
8. Iwamoto J, Takeda T, Sato Y (2006) Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Curr Med Res Opin 22: 919-928.
9. Shiraki M, Fukuchi M, Kiriyama T, et al. (2004) Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis. J Bone Miner Metab 22: 352-359.
10. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54: 370-376.
11. 3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 43: 211-220.
12. Shiraki M, Kushida K, Fukunaga M, et al. (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10: 183-192.
13. Tanizawa T, Imura K, Ishii Y, et al. (1999) Treatment with active vitamin D metabolites and concurrent treatments in the prevention of hip fractures: a retrospective study. Osteoporos Int 9: 163-170.
14. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326: 357-362.
15. Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15: 301-310.
16. 3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 89: 255-266.
17. Ushiroyama T, Ikeda A, Ueki M (2002) Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 41: 211-221.
18. 3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. J Orthop Sci 5: 546-551.
19. Orimo H, Hayashi Y, Fukunaga M, et al.; Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19: 331-337.
20. Higashi S, Shiraishi A, Hayakawa N, Kubota N (2004) Effects of raloxifene on vertebrae; Efficacy and safety of combined therapy of raloxifene and alphacalcidol. Med Drug J 40: 156-162.
21. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17: 1-10.
22. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19: 394-401.
23. Shiraishi A, Takeda S, Masaki T, et al. (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 15: 770-779.
24. Adami S, Kanis JA (1995) Perspectives: Assessment of involutional bone loss: Methodological and conceptual problems. J Bone Miner Res 10: 511-517.
25. Gatti D, Viapiana O, Lippolis I, et al. (2005) Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res 20: 1323-1326.
26. 3. Calcif Tissue Int 65: 16-22.
27. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86: 3618-3628.
28. 3 in early postmenopausal women: a population-based 5-year randomized trial. J Clin Endocrinol Metab 84: 546-552.
29. 3 (alfacalcidol) for treatment of postmenopausal bone loss. J Bone Miner Metab 24: 11-15.
30. Antoniucci DM, Vittinghoff E, Blackwell T, Black DM, Sellmeyer DE (2005) Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 90: 4566-4572.
31. Cummings SR, Karpf DB, Harris F, et al. (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281-289.
32. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87: 985-992.
33. Lind L, Lithell H, Wengle B, Wrege U, Ljunghall S (1988) A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure. Scand J Urol Nephrol 22: 219-222.